Work

SHP2 Inhibition as a Therapeutic Strategy to Target High-risk Neuroblastoma

Year: 2021
Type: dissertation
Abstract: Survival for high-risk neuroblastoma (NB) remains poor and treatment for relapsed disease rarely leads to long-term cures. Large sequencing studies of NB tumors from diagnosis have not identified common targetable driver mutations other than the 10% of tumors that harbor mutations in the anaplastic lymphoma kinase (ALK) gene. However, at NB recurrence more frequent mutations in genes in the RAS-MAPK pathway have been detected. The PTPN11-encoded tyrosine phosphatase SHP2 is an activator of the RAS pathway, and we and others have shown that pharmacologic inhibition of SHP2 suppresses the growth of various tumor types harboring KRAS mutations such as pancreatic and lung cancers. Here, we report inhibition of growth and downstream RAS-MAPK signaling in NB cells in response to treatment with the SHP2 inhibitors SHP099, II-B08, NSC-87877, and RMC-4550. Furthermore, our findings provide a rationale for the molecular and clinical potential of SHP2 inhibition in the treatment of ALK mutated NB, the most commonly mutated gene in NB tumors. Conversely, we showed that NB cell lines harboring endogenous NRASQ61K mutation (which is commonly detected at relapse) or isogenic NB cells engineered to overexpress NRASQ61K are distinctly resistant to SHP2 inhibitors. We further show that combinations of SHP2 inhibitors with other RAS-MAPK pathway inhibitors, such as the MEK inhibitor trametinib, RAF inhibitor vemurafenib and ERK inhibitor ulixertinib, are synergistic and reverse NRASQ61K-associated resistance to SHP2 inhibition in NB. Moreover, we demonstrate that combinatorial treatment with SHP2 and ALK inhibitors sensitize ALK-mutant and other MAPK-activated NB cells to ALK tyrosine kinase inhibitors and synergize in vitro. Finally, our pre-clinical studies in NB xenografts have provided evidence of the synergistic anti-tumor effects of SHP099 plus trametinib or ulixertinib treatments and showed that anti-SHP2/MAPK combinations led to an overall reduction in RAS signaling and alleviation of RTK feedback signaling in vivo. Together, these results suggest for the first time that combination therapies targeting SHP2 and other components of the RAS-MAPK pathway may be effective against conventional therapy-resistant relapsed NB including those that have acquired NRAS mutations.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: green
OpenAlex ID: W7133028612
Cites:
Cited by:
Related to: 10